CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?

Pharmacotherapy – Since its approval by the United States Food and Drug Administration in 2002, voriconazole has become a key component in the successful treatment of many invasive fungal infections, including the most common, aspergillosis and candidiasis. Despite voriconazole’s widespread use, optimizing its treatment in an individual can be challenging due to significant interpatient variability …

CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics? Read More »

Integration of Genomics in Primary Care

The American Journal of Medicine – Because gene-environment interactions are dynamic, the utility of gene-based decision support varies over time. Primary care providers will serve a key role as our patients navigate these changes.

Identifying Patients at Increased Disease Risk: Comparing Clinical Judgment and a Clinical Risk Assessment Tool

Journal of Family Medicine & Community Health – There are several barriers to the appropriate use of Family Health History (FHH)for risk management within primary care. Among these is a lack of physician confidence in their ability to identify high risk individuals and determine guideline concordant care. In this study, we compared Primary Care Providers’ …

Identifying Patients at Increased Disease Risk: Comparing Clinical Judgment and a Clinical Risk Assessment Tool Read More »

Cardiovascular Pharmacogenomics – Implications for Patients with Chronic Kidney Disease

Advances in Chronic Kidney Disease – Chronic kidney disease (CKD) is an independent risk factor for cardiovascular disease. Thus, patients with CKD often require treatment with cardiovascular drugs, such as antiplatelet, antihypertensive, anticoagulant, and lipid-lowering agents. There is significant inter-patient variability in response to cardiovascular therapies, which contributes to risk for treatment failure or adverse drug …

Cardiovascular Pharmacogenomics – Implications for Patients with Chronic Kidney Disease Read More »

UCSF TRANSPERS Center seeks Asst/Assoc. Prof of Health Services Research, Health Economics

UCSF is seeking a faculty member at the Assistant or Associate Professor rank with expertise in health services research, health economics, or a related field. Qualified applicants may also serve as the Assistant Director or Co-Director of the UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS). The Center, founded in 2008, is …

UCSF TRANSPERS Center seeks Asst/Assoc. Prof of Health Services Research, Health Economics Read More »

Implementing and Improving Automated Electronic Tumor Molecular Profiling

Journal of Oncology Practice – Oncology practice increasingly requires the use of molecular profiling of tumors to inform the use of targeted therapeutics. However, many oncologists use third-party laboratories to perform tumor genomic testing, and these laboratories may not have electronic interfaces with the provider’s electronic medical record (EMR) system.

The DNA of Pharmacy Education: CAPE Outcomes and Pharmacogenomics

The DNA of Pharmacy Education: CAPE Outcomes and Pharmacogenomics – Pharmacogenomics (PGx) is a rapidly evolving area of precision (i.e., personalized) medicine in which a patient’s genomic information is used to identify the safest and most effective treatment. While basic pharmacogenomic concepts have developed over the past 50 years, the pace of genomic research accelerated …

The DNA of Pharmacy Education: CAPE Outcomes and Pharmacogenomics Read More »

Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies

Journal of the National Cancer Institute – Loss of functional genetic polymorphisms in CYP2D6 lead to the absence of functional CYP2D6 protein in approximately 5% to 10% of whites (people of European ancestry) and 1% to 2% of those of Asian and African ancestry. In the literature, these are commonly referred to as CYP2D6–poor metabolizers (PMs). …

Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies Read More »